CAR-T Meeting 2022 | EBMT-EHA CAR T-cell highlights: new indications, new CAR-Ts & the microbiota’s impact on outcomes
Michael Loschi
• 21 Feb 2022
There were many interesting updates on chimeric antigen receptor T-cell (CAR-T) therapies presented at this year’s EBMT-EHA CAR T-cell Meeting. In this video, Michael Loschi, MD, PhD, University Hospital of Nice, Cote d’Azur University, Nice, France, shares his highlights from the meeting. Dr Loschi talks on the long-awaited developments in CAR-Ts for acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL). He also mentions advances in dual-targeting CAR-Ts and induced pluripotent stem cell (IPSC)-derived CAR-Ts, as well as updates on the role of the microbiota in CAR-T therapy outcomes. This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting which was held virtually in 2022.
